Infokiri

Saatja: EURO Influenza <[email protected]>

Saadetud: 05.03.2024 19:37

Adressaat: EURO Influenza <[email protected]>

Teema: [gisrs] Recommended viral composition of influenza vaccines for

the 2024-2025 influenza season in the northern hemisphere

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu

saatja korral palume linke ja faile mitte avada.

¬¥¬Ñ¬Ý¬Ö¬Ö ¬ã¬Ý¬Ö¬Õ¬å¬Ö¬ä ¬ä¬Ö¬Ü¬ã¬ä ¬ß¬Ñ ¬â¬å¬ã¬ã¬Ü¬à¬Þ ¬ñ¬Ù¬í¬Ü¬Ö /

This message follows in Russian

Dear colleagues,

In February 2024 the World Health Organization has convened the technical

consultation on the viral composition of influenza vaccines for the 2024-

2025 influenza season in the northern hemisphere. These consultations are

organized by WHO twice a year, in February and September, with an

advisory group of experts from WHO Collaborating Centres, H5 Reference

Laboratories and Essential Regulatory Laboratories to review available

characterization data of circulating influenza viruses generated by the

WHO Global Influenza Surveillance and Response System (GISRS) and make

recommendations on the viruses to be included in the tri- and

quadrivalent vaccines for the use during the next influenza season in

Northern and Southern hemispheres, respectively.

As an outcome of this consultation the WHO has announced which contain

the following:

Egg-based vaccines

- an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

- an A/Thailand/8/2022 (H3N2)-like virus; and

- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

- an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

- an A/Massachusetts/18/2022 (H3N2)-like virus; and

- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

For quadrivalent egg- or cell culture-based or recombinant vaccines for

use in the 2024-2025 northern hemisphere influenza season: While the

B/Yamagata lineage vaccine component should be excluded as it is no

longer warranted, where quadrivalent vaccines are still in use, the

B/Yamagata lineage component remains unchanged:

Egg-, cell- or recombinant-based Vaccines

- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

We would like to thank you all for your great contributions and

collaboration!

Best regards,

High Threat Pathogens Team / ¬¤¬â¬å¬á¬á¬Ñ ¬á¬à ¬à¬ã¬à¬Ò¬à ¬à¬á¬Ñ¬ã¬ß¬í¬Þ

¬á¬Ñ¬ä¬à¬Ô¬Ö¬ß¬Ñ¬Þ ¬¦¬²¬¢ ¬£¬°¬©

WHO Health Emergencies Program

WHO Regional Office for Europe

UN City, Marmorvej 51, 2100 Copenhagen ¨ª, Denmark

Direct: &#43;45 4533 70 00

Web:

Follow WHO on , , ,

¬¥¬Ñ¬Ý¬Ö¬Ö ¬ã¬Ý¬Ö¬Õ¬å¬Ö¬ä ¬ä¬Ö¬Ü¬ã¬ä ¬ß¬Ñ ¬â¬å¬ã¬ã¬Ü¬à¬Þ ¬ñ¬Ù¬í¬Ü¬Ö /

This message follows in Russian

¬µ¬Ó¬Ñ¬Ø¬Ñ¬Ö¬Þ¬í¬Ö ¬Ü¬à¬Ý¬Ý¬Ö¬Ô¬Ú,

¬£ ¬æ¬Ö¬Ó¬â¬Ñ¬Ý¬Ö 2024 ¬Ô¬à¬Õ¬Ñ ¬£¬ã¬Ö¬Þ¬Ú¬â¬ß¬Ñ¬ñ ¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬Ñ¬è¬Ú¬ñ

¬Ù¬Õ¬â¬Ñ¬Ó¬à¬à¬ç¬â¬Ñ¬ß¬Ö¬ß¬Ú¬ñ ¬ã¬à¬Ù¬Ó¬Ñ¬Ý¬Ñ ¬ä¬Ö¬ç¬ß¬Ú¬é¬Ö¬ã¬Ü¬å¬ð

¬Ü¬à¬ß¬ã¬å¬Ý¬î¬ä¬Ñ¬è¬Ú¬ð ¬á¬à ¬ê¬ä¬Ñ¬Þ¬Þ¬à¬Ó¬à¬Þ¬å ¬ã¬à¬ã¬ä¬Ñ¬Ó¬å

¬Ó¬Ñ¬Ü¬è¬Ú¬ß ¬á¬â¬à¬ä¬Ú¬Ó ¬ã¬Ö¬Ù¬à¬ß¬ß¬à¬Ô¬à ¬Ô¬â¬Ú¬á¬á¬Ñ ¬ß¬Ñ

¬ï¬á¬Ú¬Õ¬Ö¬Þ¬Ú¬é¬Ö¬ã¬Ü¬Ú¬Û ¬ã¬Ö¬Ù¬à¬ß 2024-2025 ¬Ô¬Ô. ¬Ó ¬ã¬Ö¬Ó¬Ö¬â¬ß¬à¬Þ

¬á¬à¬Ý¬å¬ê¬Ñ¬â¬Ú¬Ú. ¬¿¬ä¬Ú ¬Ü¬à¬ß¬ã¬å¬Ý¬î¬ä¬Ñ¬è¬Ú¬Ú

¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬å¬ð¬ä¬ã¬ñ ¬£¬°¬© ¬Õ¬Ó¬Ñ ¬â¬Ñ¬Ù¬Ñ ¬Ó ¬Ô¬à¬Õ, ¬Ó

¬æ¬Ö¬Ó¬â¬Ñ¬Ý¬Ö ¬Ú ¬ã¬Ö¬ß¬ä¬ñ¬Ò¬â¬Ö, ¬ã ¬å¬é¬Ñ¬ã¬ä¬Ú¬Ö¬Þ

¬Ü¬à¬ß¬ã¬å¬Ý¬î¬ä¬Ñ¬ä¬Ú¬Ó¬ß¬à¬Û ¬Ô¬â¬å¬á¬á¬í ¬ï¬Ü¬ã¬á¬Ö¬â¬ä¬à¬Ó ¬Ú¬Ù

¬ã¬à¬ä¬â¬å¬Õ¬ß¬Ú¬é¬Ñ¬ð¬ë¬Ú¬ç ¬è¬Ö¬ß¬ä¬â¬à¬Ó ¬£¬°¬©, ¬â¬Ö¬æ¬Ö¬â¬Ö¬ß¬ã

¬Ý¬Ñ¬Ò¬à¬â¬Ñ¬ä¬à¬â¬Ú¬Û ¬á¬à ¬Ô¬â¬Ú¬á¬á¬å H5 ¬Ú ¬Ô¬à¬Ý¬à¬Ó¬ß¬í¬ç

¬Ü¬à¬ß¬ä¬â¬à¬Ý¬î¬ß¬í¬ç ¬Ý¬Ñ¬Ò¬à¬â¬Ñ¬ä¬à¬â¬Ú¬Û ¬Õ¬Ý¬ñ ¬â¬Ñ¬ã¬ã¬Þ¬à¬ä¬â¬Ö¬ß¬Ú¬ñ ¬Ú¬Þ¬Ö¬ð¬ë¬Ú¬ç¬ã¬ñ ¬Õ¬Ñ¬ß¬ß¬í¬ç ¬à

¬ç¬Ñ¬â¬Ñ¬Ü¬ä¬Ö¬â¬Ú¬ã¬ä¬Ú¬Ü¬Ñ¬ç ¬è¬Ú¬â¬Ü¬å¬Ý¬Ú¬â¬å¬ð¬ë¬Ú¬ç ¬Ó¬Ú¬â¬å¬ã¬à¬Ó

¬Ô¬â¬Ú¬á¬á¬Ñ, ¬á¬à¬Ý¬å¬é¬Ö¬ß¬ß¬í¬ç ¬¤¬Ý¬à¬Ò¬Ñ¬Ý¬î¬ß¬à¬Û ¬ã¬Ú¬ã¬ä¬Ö¬Þ¬à¬Û

¬£¬°¬© ¬á¬à ¬ï¬á¬Ú¬Õ¬ß¬Ñ¬Õ¬Ù¬à¬â¬å ¬Ù¬Ñ ¬Ô¬â¬Ú¬á¬á¬à¬Þ ¬Ú

¬á¬â¬Ú¬ß¬ñ¬ä¬Ú¬ð ¬à¬ä¬Ó¬Ö¬ä¬ß¬í¬ç ¬Þ¬Ö¬â (¬¤¬³¬¿¬¤¬°) ¬Ú

¬á¬â¬Ö¬Õ¬à¬ã¬ä¬Ñ¬Ó¬Ý¬Ö¬ß¬Ú¬ñ ¬â¬Ö¬Ü¬à¬Þ¬Ö¬ß¬Õ¬Ñ¬è¬Ú¬Ú ¬á¬à

¬Ó¬Ú¬â¬å¬ã¬Ñ¬Þ, ¬Ü¬à¬ä¬à¬â¬í¬Ö ¬Õ¬à¬Ý¬Ø¬ß¬í ¬Ò¬í¬ä¬î ¬Ó¬Ü¬Ý¬ð¬é¬Ö¬ß¬í ¬Ó

¬ä¬â¬Ö¬ç- ¬Ú ¬é¬Ö¬ä¬í¬â¬Ö¬ç¬Ó¬Ñ¬Ý¬Ö¬ß¬ä¬ß¬í¬Ö ¬Ó¬Ñ¬Ü¬è¬Ú¬ß¬í ¬Õ¬Ý¬ñ

¬Ú¬ã¬á¬à¬Ý¬î¬Ù¬à¬Ó¬Ñ¬ß¬Ú¬ñ ¬Ó ¬ã¬Ý¬Ö¬Õ¬å¬ð¬ë¬Ö¬Þ ¬ã¬Ö¬Ù¬à¬ß¬Ö

¬Ô¬â¬Ú¬á¬á¬Ñ ¬Ó ¬³¬Ö¬Ó¬Ö¬â¬ß¬à¬Þ ¬Ú ¬À¬Ø¬ß¬à¬Þ ¬á¬à¬Ý¬å¬ê¬Ñ¬â¬Ú¬ñ¬ç

¬ã¬à¬à¬ä¬Ó¬Ö¬ä¬ã¬ä¬Ó¬Ö¬ß¬ß¬à.

¬±¬à ¬Ú¬ä¬à¬Ô¬Ñ¬Þ ¬ï¬ä¬à¬Û ¬Ü¬à¬ß¬ã¬å¬Ý¬î¬ä¬Ñ¬è¬Ú¬Ú ¬£¬°¬©

¬à¬Ò¬ì¬ñ¬Ó¬Ú¬Ý¬Ñ (¬ß¬Ñ ¬Ñ¬ß¬Ô¬Ý¬Ú¬Û¬ã¬Ü¬à¬Þ ¬ñ¬Ù¬í¬Ü¬Ö), ¬Ü¬à¬ä¬à¬â¬í¬Ö

¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ä ¬ã¬Ý¬Ö¬Õ¬å¬ð¬ë¬Ö¬Ö:

¬£¬Ñ¬Ü¬è¬Ú¬ß¬í, ¬Ü¬å¬Ý¬î¬ä¬Ú¬Ó¬Ú¬â¬å¬Ö¬Þ¬í¬Ö ¬ß¬Ñ ¬Ü¬å¬â¬Ú¬ß¬í¬ç

¬ï¬Þ¬Ò¬â¬Ú¬à¬ß¬Ñ¬ç

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û A/Victoria/4897/2022 (H1N1)pdm09;

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û A/Thailand/8/2022 (H3N2);

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û B/Austria/1359417/2021 (¬Ý¬Ú¬ß¬Ú¬ñ

B/Victoria).

¬£¬Ñ¬Ü¬è¬Ú¬ß¬í, ¬Ó¬í¬â¬Ñ¬ë¬Ö¬ß¬ß¬í¬Ö ¬Ó ¬Ü¬å¬Ý¬î¬ä¬å¬â¬Ö ¬Ü¬Ý¬Ö¬ä¬à¬Ü,

¬Ú¬Ý¬Ú ¬â¬Ö¬Ü¬à¬Þ¬Ò¬Ú¬ß¬Ñ¬ß¬ä¬ß¬í¬Ö ¬Ó¬Ñ¬Ü¬è¬Ú¬ß¬í

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û A/Wisconsin/67/2022 (H1N1)pdm09;

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û A/Massachusetts/18/2022 (H3N2);

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û B/Austria/1359417/2021 (¬Ý¬Ú¬ß¬Ú¬ñ

B/Victoria).

¬¥¬Ý¬ñ ¬é¬Ö¬ä¬í¬â¬Ö¬ç¬Ó¬Ñ¬Ý¬Ö¬ß¬ä¬ß¬í¬ç ¬Ó¬Ñ¬Ü¬è¬Ú¬ß ,

¬Ó¬í¬â¬Ñ¬ë¬Ö¬ß¬ß¬í¬ç ¬ß¬Ñ ¬Ü¬å¬â¬Ú¬ß¬í¬ç ¬ï¬Þ¬Ò¬â¬Ú¬à¬ß¬Ñ¬ç,

¬Ó¬í¬â¬Ñ¬ë¬Ö¬ß¬ß¬í¬ç ¬Ó ¬Ü¬å¬Ý¬î¬ä¬å¬â¬Ö ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬Ú¬Ý¬Ú

¬â¬Ö¬Ü¬à¬Þ¬Ò¬Ú¬ß¬Ñ¬ß¬ä¬ß¬í¬ç ¬Ó¬Ñ¬Ü¬è¬Ú¬ß, ¬á¬â¬Ö¬Õ¬ß¬Ñ¬Ù¬ß¬Ñ¬é¬Ö¬ß¬ß¬í¬ç

¬Õ¬Ý¬ñ ¬á¬â¬Ú¬Þ¬Ö¬ß¬Ö¬ß¬Ú¬ñ ¬Ó ¬ï¬á¬Ú¬Õ¬Ö¬Þ¬Ú¬é¬Ö¬ã¬Ü¬Ú¬Û ¬ã¬Ö¬Ù¬à¬ß

2024-2025 ¬Ô¬Ô. ¬Ó ¬³¬Ö¬Ó¬Ö¬â¬ß¬à¬Þ ¬á¬à¬Ý¬å¬ê¬Ñ¬â¬Ú¬Ú: ¬Ó ¬ä¬à

¬Ó¬â¬Ö¬Þ¬ñ ¬Ü¬Ñ¬Ü ¬Ü¬à¬Þ¬á¬à¬ß¬Ö¬ß¬ä ¬Ó¬Ñ¬Ü¬è¬Ú¬ß¬í ¬Ý¬Ú¬ß¬Ú¬Ú B/Yamagata

¬ã¬Ý¬Ö¬Õ¬å¬Ö¬ä ¬Ú¬ã¬Ü¬Ý¬ð¬é¬Ú¬ä¬î, ¬á¬à¬ã¬Ü¬à¬Ý¬î¬Ü¬å ¬à¬ß ¬Ò¬à¬Ý¬î¬ê¬Ö

¬ß¬Ö ¬ñ¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ ¬à¬á¬â¬Ñ¬Ó¬Õ¬Ñ¬ß¬ß¬í¬Þ, ¬ä¬Ñ¬Þ, ¬Ô¬Õ¬Ö ¬Ó¬ã¬Ö

¬Ö¬ë¬Ö ¬Ú¬ã¬á¬à¬Ý¬î¬Ù¬å¬ð¬ä¬ã¬ñ ¬é¬Ö¬ä¬í¬â¬Ö¬ç¬Ó¬Ñ¬Ý¬Ö¬ß¬ä¬ß¬í¬Ö

¬Ó¬Ñ¬Ü¬è¬Ú¬ß¬í, ¬Ü¬à¬Þ¬á¬à¬ß¬Ö¬ß¬ä ¬Ý¬Ú¬ß¬Ú¬Ú B/Yamagata ¬à¬ã¬ä¬Ñ¬Ö¬ä¬ã¬ñ

¬ß¬Ö¬Ú¬Ù¬Þ¬Ö¬ß¬ß¬í¬Þ:

* ¬Ó¬Ú¬â¬å¬ã, ¬á¬à¬Õ¬à¬Ò¬ß¬í¬Û B/Phuket/3073/2013 (¬Ý¬Ú¬ß¬Ú¬ñ

B/Yamagata).

¬®¬í ¬ç¬à¬ä¬Ö¬Ý¬Ú ¬Ò¬í ¬á¬à¬Ò¬Ý¬Ñ¬Ô¬à¬Õ¬Ñ¬â¬Ú¬ä¬î ¬Ó¬ã¬Ö¬ç ¬Ó¬Ñ¬ã ¬Ù¬Ñ

¬Ó¬Ñ¬ê ¬Ó¬Ü¬Ý¬Ñ¬Õ ¬Ú ¬ã¬à¬ä¬â¬å¬Õ¬ß¬Ú¬é¬Ö¬ã¬ä¬Ó¬à!

¬³ ¬å¬Ó¬Ñ¬Ø¬Ö¬ß¬Ú¬Ö¬Þ,

¬¤¬â¬å¬á¬á¬Ñ ¬á¬à ¬à¬ã¬à¬Ò¬à ¬à¬á¬Ñ¬ã¬ß¬í¬Þ ¬á¬Ñ¬ä¬à¬Ô¬Ö¬ß¬Ñ¬Þ ¬¦¬²¬¢

£¡©

WHO Health Emergencies Program

WHO Regional Office for Europe

UN City, Marmorvej 51, 2100 Copenhagen ¨ª, Denmark

Direct: &#43;45 4533 70 00

Web:

Follow WHO on , , ,